LifeMD (NASDAQ: LFMD) is scheduled to announce its fourth quarter 2025 earnings on March 9, 2026, after the market closes. Analysts project that the telehealth company will report earnings of ($0.01) per share and revenue of $48.57 million for the quarter. Investors will be able to access the details during the earnings call set to take place at 4:30 PM ET.
The stock opened at $3.00 on Friday, reflecting a challenging year for the company. LifeMD’s stock has fluctuated significantly, with a fifty-two week low of $2.56 and a high of $15.84. Currently, the fifty-day moving average stands at $3.30, while the two-hundred-day moving average is $4.63. With a market capitalization of $144.42 million, the company has a price-to-earnings ratio of -17.65 and a beta of 1.92, indicating higher volatility compared to the broader market.
Analysts’ Perspectives on LifeMD Stock
Recent reports from various research firms provide insight into LifeMD’s stock performance. Lake Street Capital recently lowered its price target from $14.00 to $8.00 while maintaining a “buy” rating. Conversely, Zacks Research upgraded its rating from “strong sell” to “hold.” In a report from Loop Capital, the target price was also set at $8.00. Additionally, HC Wainwright reduced its price target from $13.00 to $9.00, maintaining a “buy” rating. Meanwhile, Weiss Ratings reaffirmed a “sell (e+)” rating.
A total of six analysts have rated LifeMD as a “buy,” while two have given it a “hold” rating, and one has issued a “sell” rating. According to data from MarketBeat, the consensus rating is “Moderate Buy” with a target price of $9.25.
Insider Trading Activity
In a related development, Chief Marketing Officer Jessica Friedeman sold 15,000 shares of LifeMD on December 9, 2025, at an average price of $3.61, totaling $54,150. Following the sale, Friedeman retains 205,000 shares valued at approximately $740,050, representing a 6.82% decrease in her ownership. This transaction was disclosed to the Securities and Exchange Commission and is accessible through their website. Insiders currently hold 18.40% of the company’s stock.
Institutional investors have also been active in trading LifeMD shares. Tower Research Capital LLC increased its stake by 110.4% in the second quarter, now holding 4,674 shares valued at $64,000. Quarry LP acquired a new position in the third quarter worth approximately $52,000. Legal & General Group Plc raised its holdings by 187.4% in the second quarter, now owning 10,144 shares valued at $138,000. Additionally, Caitong International Asset Management Co. Ltd and Hudson Bay Capital Management LP purchased new stakes valued at approximately $36,000 and $153,000 respectively. Institutional and hedge funds collectively own 35.52% of LifeMD’s stock.
LifeMD, based in the United States, specializes in on-demand, membership-based telehealth services. The company connects patients with board-certified healthcare providers for various medical needs through its digital platform and mobile applications. LifeMD’s core services include personalized care plans, prescription fulfillment, lab testing, and delivery across multiple specialties, including men’s health, hormonal therapy, and primary care.
